Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Medical Developments International Limited ( (AU:MVP) ).
Medical Developments International Limited announced a change in the director’s interest, with Director Paul Townsend acquiring 25,000 fully paid ordinary shares on the market, valued at $16,785.31. This acquisition reflects an increase in the director’s stake in the company, potentially indicating confidence in the company’s future performance and impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
More about Medical Developments International Limited
Medical Developments International Limited operates in the medical industry, focusing on the production and distribution of medical products and services. The company’s primary offerings include medical devices and pharmaceuticals, with a market focus on improving patient care and outcomes.
Average Trading Volume: 155,301
Technical Sentiment Signal: Buy
Current Market Cap: A$76.61M
For a thorough assessment of MVP stock, go to TipRanks’ Stock Analysis page.